Compounds > hydrazine
Page last updated: 2024-08-21

hydrazine and Multiple Myeloma

hydrazine has been researched along with Multiple Myeloma in 82 studies

Research

Studies (82)

TimeframeStudies, this research(%)All Research%
pre-199014 (17.07)18.7374
1990's1 (1.22)18.2507
2000's2 (2.44)29.6817
2010's18 (21.95)24.3611
2020's47 (57.32)2.80

Authors

AuthorsStudies
Green, K; Hashmi, H1
Biran, N; Breeze, J; Chari, A; Choquet, S; Cornell, RF; Costa, L; Daniele, P; Delforge, M; Dimopoulos, MA; Dingli, D; Doyen, C; Engelhardt, M; Facon, T; Gavriatopoulou, M; Hoffman, JE; Kaminetzky, D; Kauffman, M; Laurent, F; Levy, M; Li, L; Lionel, K; Meuleman, N; Mohty, M; Moreau, P; Nooka, A; Parker, T; Podar, K; Raab, M; Richardson, P; Richter, J; Schiller, G; Schreder, M; Shacham, S; Shah, J; Siegel, D; Sundar, J; Tremblay, G; Tuchman, S; Vij, R; Vlummens, P; Vogl, D; Weisel, K1
Ferrante, SA; Gorsh, B; Hogea, C; Hughes, R; Kapetanakis, V; Popat, R; Prawitz, T; Sarri, G; Suvannasankha, A; Wang, F; Willson, J1
Ando, K; Kawada, H; Kitamura, Y; Ogawa, Y; Ogiya, D; Suzuki, R1
Ammu, S; Bahlis, NJ; Baljevic, M; Ben-Shahar, O; Bensinger, WI; Bentur, OS; Biran, N; Callander, NS; Chen, CI; DeCastro, A; Gasparetto, C; Kauffman, M; Kotb, R; LeBlanc, R; Lentzsch, S; Lipe, B; Madan, S; Rossi, AC; Schiller, GJ; Sebag, M; Shacham, S; Shah, J; Sutherland, HJ; Tuchman, SA; Van Domelen, D; Venner, CP; White, D; Zhang, C; Zhou, T1
Chalopin, T; Nsiala, L1
Arazy, M; Auner, HW; Benjamin, R; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Garg, MK; Gavriatopoulou, M; Grosicki, S; Hájek, R; Kauffman, MG; Leleu, X; Levy, Y; Mateos, MV; Moreau, P; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Sinha, DK; Venner, CP1
Chari, A; Costa, LJ; Gasparetto, CJ; Jagannath, S; Lentzsch, S; Mikhael, J; Nooka, AK; Richardson, PG; Siegel, DS1
Che, J; Dong, X; Guo, Y; Jin, X; Lu, Y; Qu, B; Shen, Z; Shi, Q; Tong, L; Wu, Y; Xu, Y; Yan, S; Yang, H; Zhuang, W1
An, G; Cai, Z; Chang, C; Chen, L; Chen, W; Chen, X; Fang, B; Fu, C; Fu, W; Gao, S; Jing, H; Li, F; Liu, J; Liu, Z; Lynch, K; Qiu, L; Wang, A; Wei, Y; Weng, J; Xia, Z; Xiang, W; Yu, Y; Yu, Z1
Chen, SL; Chen, XQ; Dai, YJ; Hu, F; Li, XP; Liang, Y; Lu, YX; Wang, DW1
Ben-Shahar, O; Cass, M; Kashyap, T; Landesman, Y; McDonald, AB1
Agte, S; Aleman, A; Bhalla, S; Chari, A; Cho, HJ; Ghodke-Puranik, Y; Jagannath, S; Jiang, J; Laganà, A; Landesman, Y; Leshchenko, V; Madduri, D; Melnekoff, DT; Parekh, S; Restrepo, P; Richard, S; Richter, J; Walker, CJ1
Banerjee, A; Berdeja, JG; Deraedt, W; Diels, J; Jackson, CC; Jagannath, S; Krishnan, A; Martin, T; Nesheiwat, T; Schecter, JM; Usmani, SZ; Valluri, S; Van Sanden, S; Vogel, M; Weisel, K; Yalniz, F; Yeh, TM1
Garate, GM; Ochoa, PA; Remaggi, G1
Goldsmith, SR; Liu, L; Shiah, K1
Bartley, BR; Doan, HQ; Landes, JR; Moore, SA; Rady, PL; Tyring, SK1
Daelemans, D; Deconick, T; Kwanten, B; Landesman, Y; Walker, C; Wang, F1
Feng, Y; Gao, Q; Huang, J; Li, J; Li, L; Li, Q; Lin, Z; Liu, X; Luo, H; Niu, T; Sun, C; Wang, F; Wang, X; Wen, J; Xu, J; Zhai, X; Zhang, L; Zhang, Y; Zhao, F; Zheng, Y1
Syed, YY1
Chang, H; Chari, A; Choquet, S; Cole, C; Comenzo, RL; Cornell, RF; Costa, LJ; Crochiere, M; Delforge, M; Dimopoulos, M; Dingli, D; Doyen, C; Engelhardt, M; Facon, T; Frenzel, L; Gavriatopoulou, M; Hoffman, JE; Huff, CA; Illmer, T; Jagannath, S; Kaminetzky, D; Karlin, L; Kauffman, MG; Landesman, Y; Levy, M; Li, L; Lonial, S; Meuleman, N; Mohty, M; Moreau, P; Nooka, AK; Parekh, S; Parker, TL; Perrot, A; Picklesimer, C; Podar, K; Raab, MS; Richardson, PG; Richter, J; Saint-Martin, JR; Schiller, G; Schreder, M; Shacham, S; Shah, J; Stewart, AK; Tang, S; Tuchman, S; Vij, R; Vlummens, P; Vogl, DT; Weisel, KC; Yee, AJ1
Stirrups, R1
Romero, D1
Jhaveri, KD; Wanchoo, R1
Chari, A; Jagannath, S; Vogl, DT1
Baz, R; Nishihori, T1
Chari, A; Jagannath, S; Podar, K; Richardson, PG; Shah, J1
Chung, D; Diab, V; Drullinsky, P; Giralt, S; Hassoun, H; Hultcrantz, M; Korde, N; Lahoud, O; Landau, H; Landgren, O; Lendvai, N; Lesokhin, A; Mailankody, S; Mastey, D; Salcedo, M; Schlossman, J; Scordo, M; Shah, G; Shah, U; Smith, E; Werner, K1
Gill, J; Haslam, A; Prasad, V1
Chakraborty, R; Efficace, F1
Abonour, R; Bahlis, N; Baz, R; Berdeja, JG; Chai, Y; Chari, A; Chen, C; Choquet, S; Cornell, RF; Dimopoulos, MA; Dingli, D; Gasparetto, C; Gavriatopoulou, M; Hofmeister, CC; Huff, CA; Jagannath, S; Jakubowiak, A; Kauffman, MG; Lentzsch, S; Li, K; Li, L; Lonial, S; Mohty, M; Moreau, P; Nooka, AK; Parker, TL; Reece, D; Richter, J; Shacham, S; Shah, J; Siegel, D; Tuchman, S; Unger, TJ; Vogl, DT; Weisel, KC; White, D; Yee, AJ1
Chari, A; DeCastro, A; Jagannath, S; Jakubowiak, A; Jasielec, J; Kauffman, M; Shacham, S; Shah, J; Unger, TJ; Vogl, DT1
Chari, A; Costa, LJ; Faiman, B; Gleason, C; Jagannath, S; Lentzch, S; Mikhael, J; Nooka, AK; Noonan, KR; Richardson, PG; Siegel, D1
Ahmann, GJ; Bergsagel, PL; Bonolo de Campos, C; Braggio, E; Bruins, LA; Darvish, SA; Dingli, D; Fonseca, R; Henderson, KJ; Kapoor, P; Kruse, JJ; Kumar, SK; Larsen, JT; Lopez Armenta, ID; Meurice, N; Petit, JL; Polito, AN; Reeder, CB; Stewart, AK; Stewart, WM; Tian, S; Wang, P; Wang, X; Zhu, YX1
Jagannath, S; Richard, S; Richter, J1
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J1
Avigdor, A; Geva, M; Magen, H; Nagler, A; Volchik, Y1
Biran, N; Callander, N; Chari, A; Chhabra, S; Cornell, R; Costa, L; Fiala, MA; Gahvari, Z; Gandhi, U; Godby, K; Gupta, R; Hari, P; Jagannath, S; Jagosky, M; Kang, Y; Kansagra, A; Kauffman, M; Kodali, S; Kumar, SK; Lakshman, A; Liedtke, M; Lonial, S; Ma, X; Malek, E; Mansour, J; McGehee, EF; Neppalli, A; Paul, B; Richardson, P; Scott, EC; Shacham, S; Shah, J; Siegel, DS; Tang, S; Umyarova, E; Usmani, SZ; Varnado, W; Vij, R1
Chari, A; Cho, HJ; DeCastro, A; Jagannath, S; Landesman, Y; Madduri, D; Mouhieddine, TH; Parekh, S; Richter, J; Shah, J1
Bauer, AA; Cubitt, CL; Cui, Y; Dalton, WS; Dawson, JL; Gomez, JA; Kim, J; Nishihori, T; Sullivan, DM; Turner, JG1
Anderson, LD; Arazy, M; Auner, HW; Badros, A; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Facon, T; Garg, M; Gavriatopoulou, M; Grosicki, S; Hajek, R; Jagannath, S; Kauffman, MG; Kriachok, I; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Spicka, I; Stevens, DA; Usenko, G; Venner, CP1
Anderson, LD; Arazy, M; Auner, HW; Badros, AZ; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Facon, T; Garg, M; Gavriatopoulou, M; Grosicki, S; Hájek, R; Jagannath, S; Jeha, J; Kauffman, MG; Kriachok, I; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Špička, I; Stevens, DA; Usenko, G; Venner, CP1
Forsberg, P; Mark, TM; Sherbenou, D; Stalker, M1
Ayers, D; Cope, S; Davies, FE; Delforge, M; Dhanasiri, S; Hege, K; Jansen, JP; Mojebi, A; Rodriguez-Otero, P; Weisel, K1
Delimpasi, S; Dimopoulos, MA; Grosicki, S; Kauffman, MG; Moreau, P; Richardson, PG1
Bahlis, NJ; Biran, N; Chari, A; Gasparetto, C; Jagannath, S; Lonial, S; Mo, CC; Nooka, AK; Richardson, P; Siegel, D1
Anderson, LD; Arazy, M; Auner, HW; Badros, A; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Chang, H; Chari, A; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Facon, T; Garg, M; Grosicki, S; Hajek, R; Jagannath, S; Kauffman, MG; Kriachok, I; Landesman, Y; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richard, S; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Spicka, I; Stevens, DA; Usenko, G; Venner, CP1
Bar, N; Di, M; Giri, S; Huntington, SF; Parker, T; Patel, KK1
Anderson, LD; Auner, HW; Bahlis, NJ; Beaumont, JL; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Facon, T; Garg, MK; Grosicki, S; Hájek, R; Hudgens, S; Illmer, T; Jagannath, S; Kauffman, M; Kriachok, I; Leleu, X; Leong, H; Levy, M; Ma, X; Pour, L; Quach, H; Richardson, P; Sanchez, L; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Špička, I; Stevens, DA; Tang, S; Usenko, G; Venner, C; Yu, H1
Abid, H; Abid, MB; Wu, JF1
Dolph, M; Leong, H; Tremblay, G1
Castellon, C; Chaquette, R; Meleveedu, KS; Onkarappa Mangala, Y; Perez Rodriguez, A1
Bhalla, S; Chari, A; Cho, H; Dhadwal, A; Florendo, E; Jagannath, S; Jiang, G; Lagana, A; Madduri, D; Mancia, IS; Parekh, S; Richter, J; Thomas, J1
Abonour, R; Ahmann, G; Baz, R; Bhutani, D; Chari, A; Choe-Juliak, C; Cole, C; Cornell, RF; Costa, LJ; Dingli, D; Fonseca, R; Hoffman, JE; Huff, CA; Jagannath, S; Jakubowiak, A; Kaminetzky, D; Kauffman, M; Lopez, I; Nooka, A; Parker, TL; Picklesimer, CD; Richter, J; Saint-Martin, JR; Schiller, G; Shacham, S; Siegel, D; Stewart, AK; Van Wier, S; Vij, R; Vogl, DT; Yee, AJ; Zonder, J1
Burki, TK1
Baloglu, E; Chari, A; Cornell, RF; Gandhi, UH; Senapedis, W; Unger, TJ; Vogl, D1
Aljama, MA; Dingli, D; Sidiqi, MH1
Gourd, E1
Chari, A; Cole, CE; Hycner, T; Jakubowiak, AJ; Jasielec, JK; Karrison, T; McIver, A; Mikhael, J; Nam, J; Rosebeck, S; Rosenbaum, CA; Severson, E; Stephens, LA; Tinari, K; Turowski, A; Zimmerman, TM; Zonder, JA1
Abayasekara, N; Berliner, N; Jeong, JY; Laubach, J; Levine, MS; Vanasse, GJ1
Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Kauffman, M; Kraftson, SJ; Maxwell, SP; Mayampurath, A; McCauley, D; Rosebeck, S; Shacham, S; Volchenboum, SL1
Chen, G; Liu, G; Liu, Q; Tao, B; Xiong, H; Yu, Y; Zhu, Q1
Baz, R; Dai, Y; Dalton, WS; Dawson, JL; Grant, S; Kauffman, M; Meads, M; Shacham, S; Shain, KH; Sullivan, DM; Turner, JG1
Bauer, AA; Dai, Y; Dawson, JL; Gomez, J; Grant, S; Kashyap, T; Landesman, Y; Meads, M; Shain, KH; Sullivan, DM; Turner, JG1
Desai, A; Gong, T; Lu, P; Wang, M; Zeng, D; Zhang, K1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A1
AMIEL, JL; CATTAN, A; MATHE, G; SCHLUMBERGER, JR; SCHNEIDER, M; SCHWARZENBERG, L2
Tear, S1
Arroyo de la Fuente, F; Lasheras Garde, J; Triginer Boixeda, J1
Fujii, E; Hiki, Y; Hotta, K; Ishii-Karakasa, I; Iwase, H; Kobayashi, Y1
Abel, CA; Grey, HM1
Hiramatsu, S; Inai, S; Nagaki, K; Tanabe, S1
Alexanian, R; Frei, E; Howe, CD; Leary, WV; Samuels, ML1
Armstrong, JG1
Danieli, G1
el-Akkad, SM; Garrett, MJ; Glazebrook, GA; Shakir, MA1
Clément, F3
Martin, H; Schubert, JC1

Reviews

14 review(s) available for hydrazine and Multiple Myeloma

ArticleYear
The 'comeback' of Selinexor: From toxic to tolerable.
    Current problems in cancer, 2022, Volume: 46, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Multiple Myeloma; Triazoles

2022
Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas.
    Current opinion in oncology, 2022, 09-01, Volume: 34, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Lymphoma, Non-Hodgkin; Multiple Myeloma; Triazoles

2022
The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:5

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Cell Line, Tumor; Humans; Hydrazines; Karyopherins; Male; Multiple Myeloma; Triazoles

2023
Selinexor: First Global Approval.
    Drugs, 2019, Volume: 79, Issue:13

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Triazoles

2019
Selinexor for the treatment of multiple myeloma.
    Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:4

    Topics: Active Transport, Cell Nucleus; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Nucleus; Clinical Trials as Topic; Dexamethasone; Drug Evaluation, Preclinical; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Prognosis; Receptors, Cytoplasmic and Nuclear; Triazoles

2020
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:6

    Topics: Consensus; Humans; Hydrazines; Multiple Myeloma; Practice Guidelines as Topic; Triazoles

2020
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.
    Future oncology (London, England), 2020, Volume: 16, Issue:19

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Survival Rate; Triazoles

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses

2021
Selinexor for the treatment of patients with previously treated multiple myeloma.
    Expert review of hematology, 2021, Volume: 14, Issue:8

    Topics: Humans; Hydrazines; Karyopherins; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Triazoles

2021
Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 154

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Hydrazines; Infections; Multiple Myeloma; Recurrence; Triazoles

2021
Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:5

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Treatment Outcome; Triazoles

2018
Therapy for relapsed multiple myeloma.
    Panminerva medica, 2018, Volume: 60, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Decision Making; Gene Expression Profiling; Humans; Hydrazines; Immunotherapy; In Situ Hybridization, Fluorescence; Multiple Myeloma; Neoplasm Recurrence, Local; Stem Cell Transplantation; Sulfonamides; Symptom Assessment; Transplantation, Autologous; Triazoles; Watchful Waiting

2018
Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
    Oncotarget, 2017, Feb-07, Volume: 8, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Boron Compounds; Congresses as Topic; Glycine; Humans; Hydrazines; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Thiadiazoles; Treatment Outcome; Triazoles

2017
[Novel medical treatment modalities in hematology].
    Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

    Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine

2008

Trials

15 trial(s) available for hydrazine and Multiple Myeloma

ArticleYear
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
    BMC cancer, 2021, Sep-06, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Survival Rate; Triazoles

2021
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
    British journal of cancer, 2022, Volume: 126, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Oligopeptides; Survival Analysis; Translocation, Genetic; Treatment Outcome; Triazoles

2022
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
    American journal of hematology, 2022, 03-01, Volume: 97, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Hydrazines; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Survival Rate; Triazoles

2022
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
    BMC medicine, 2022, 04-05, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Multiple Myeloma; Proteasome Inhibitors; Triazoles

2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HOR
    Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hydrazines; Melphalan; Multiple Myeloma; Triazoles

2022
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
    The New England journal of medicine, 2019, 08-22, Volume: 381, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Humans; Hydrazines; Intention to Treat Analysis; Karyopherins; Male; Middle Aged; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Survival Analysis; Thrombocytopenia; Triazoles; Young Adult

2019
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses

2021
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
    American journal of hematology, 2021, Volume: 96, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Dexamethasone; Disease-Free Survival; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Survival Rate; Triazoles

2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
    American journal of hematology, 2021, 09-01, Volume: 96, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cytogenetic Analysis; Dexamethasone; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Treatment Outcome; Triazoles; Young Adult

2021
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
    American journal of hematology, 2021, 10-01, Volume: 96, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Triazoles

2021
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 03-20, Volume: 36, Issue:9

    Topics: Active Transport, Cell Nucleus; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Receptors, Cytoplasmic and Nuclear; Triazoles

2018
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
    British journal of haematology, 2019, Volume: 186, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Prognosis; Recurrence; Retreatment; Treatment Outcome; Triazoles

2019
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
    Journal of hematology & oncology, 2016, 08-24, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Cell Line, Tumor; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Heterografts; Humans; Hydrazines; Karyopherins; Mice; Multiple Myeloma; Polyethylene Glycols; Receptors, Cytoplasmic and Nuclear; Survival Rate; Topoisomerase II Inhibitors; Triazoles; Tumor Burden

2016
Clinical trials with N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride in malignant lymphoma and other disseminated neoplasia.
    Cancer, 1967, Volume: 20, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Amines; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Hodgkin Disease; Humans; Hydrazines; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multiple Myeloma; Mycosis Fungoides; Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor

1967

Other Studies

54 other study(ies) available for hydrazine and Multiple Myeloma

ArticleYear
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
    Advances in therapy, 2021, Volume: 38, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Standard of Care; Triazoles

2021
Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma.
    International journal of hematology, 2022, Volume: 115, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Hydrazines; Multiple Myeloma; Triazoles; Tumor Cells, Cultured

2022
[New European approval: Selinexor for triple class refractory multiple myeloma].
    Bulletin du cancer, 2022, Volume: 109, Issue:1

    Topics: Administration, Oral; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Europe; Humans; Hydrazines; Immunomodulating Agents; Membrane Glycoproteins; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Triazoles

2022
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
    Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consensus; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles

2022
Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells.
    European journal of medicinal chemistry, 2022, May-05, Volume: 235

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Hydrazines; Karyopherins; Multiple Myeloma; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Triazoles

2022
Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma.
    International immunopharmacology, 2022, Volume: 108

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Drug Resistance, Neoplasm; Hepatitis A Virus Cellular Receptor 2; Humans; Hydrazines; Karyopherins; Multidrug Resistance-Associated Proteins; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, Cytoplasmic and Nuclear; Triazoles

2022
A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation.
    The American journal of case reports, 2022, Apr-21, Volume: 23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles

2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
    JCO precision oncology, 2022, Volume: 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles

2022
Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series.
    The American journal of case reports, 2022, Jul-14, Volume: 23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles

2022
E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 160

    Topics: Active Transport, Cell Nucleus; Humans; Hydrazines; Karyopherins; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Suppressor of Cytokine Signaling Proteins

2023
RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor.
    Cancer letters, 2024, Jan-01, Volume: 580

    Topics: Animals; Cell Line, Tumor; Heterogeneous-Nuclear Ribonucleoprotein U; Humans; Hydrazines; Karyopherins; Mice; Multiple Myeloma; RNA; RNA-Binding Proteins

2024
Selinexor-dexamethasone for refractory multiple myeloma.
    The Lancet. Oncology, 2019, Volume: 20, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Dexamethasone; Humans; Hydrazines; Multicenter Studies as Topic; Multiple Myeloma; Retreatment; Triazoles

2019
Responses to selinexor in multiple myeloma.
    Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:11

    Topics: Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles

2019
Selinexor for Refractory Multiple Myeloma.
    The New England journal of medicine, 2019, 11-14, Volume: 381, Issue:20

    Topics: Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles

2019
Selinexor for Refractory Multiple Myeloma. Reply.
    The New England journal of medicine, 2019, 11-14, Volume: 381, Issue:20

    Topics: Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles

2019
Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?
    Expert opinion on drug safety, 2020, Volume: 19, Issue:2

    Topics: Active Transport, Cell Nucleus; Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Multiple Myeloma; Triazoles

2020
Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions.
    Mayo Clinic proceedings, 2020, Volume: 95, Issue:2

    Topics: Advisory Committees; Drug Approval; Humans; Hydrazines; Multiple Myeloma; Triazoles; United States; United States Food and Drug Administration

2020
Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma.
    British journal of haematology, 2020, Volume: 189, Issue:3

    Topics: Humans; Hydrazines; Multiple Myeloma; Quality of Life; Survival Analysis; Triazoles

2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
    Leukemia, 2020, Volume: 34, Issue:9

    Topics: Aged; Antineoplastic Agents; Appetite; Clinical Trials as Topic; Diarrhea; Fatigue; Female; Humans; Hydrazines; Hyponatremia; Male; Middle Aged; Multiple Myeloma; Nausea; Thrombocytopenia; Triazoles

2020
Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy.
    British journal of haematology, 2020, Volume: 189, Issue:4

    Topics: Adult; Aged; Cell- and Tissue-Based Therapy; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Receptors, Chimeric Antigen; Triazoles

2020
"Direct to Drug" screening as a precision medicine tool in multiple myeloma.
    Blood cancer journal, 2020, 05-11, Volume: 10, Issue:5

    Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Hydrazines; Multiple Myeloma; Precision Medicine; Sulfonamides; Triazoles; Tumor Cells, Cultured

2020
Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:12

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Hydrazines; Middle Aged; Multiple Myeloma; Triazoles

2020
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
    Annals of hematology, 2021, Volume: 100, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles

2021
Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
    Cancer research, 2020, 12-01, Volume: 80, Issue:23

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exportin 1 Protein; Fanconi Anemia Complementation Group D2 Protein; Humans; Hydrazines; Karyopherins; Melphalan; Mice, Inbred NOD; Multiple Myeloma; Nestin; Receptors, Cytoplasmic and Nuclear; Triazoles; Ubiquitination; Xenograft Model Antitumor Assays

2020
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
    American journal of hematology, 2021, 06-01, Volume: 96, Issue:6

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Administration Schedule; Female; Frailty; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Triazoles

2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
    Journal of hematology & oncology, 2021, 04-13, Volume: 14, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Multiple Myeloma; Triazoles

2021
Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation.
    Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Transplantation, Homologous; Treatment Outcome; Triazoles

2021
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles; United States

2021
Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply.
    Lancet (London, England), 2021, 05-01, Volume: 397, Issue:10285

    Topics: Bortezomib; Boston; Control Groups; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles

2021
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Triazoles

2021
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
    PharmacoEconomics, 2021, Volume: 39, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Boston; Cost-Benefit Analysis; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles

2021
First case report of tumor lysis syndrome and acute renal failure after selinexor use in multiple myeloma.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:14

    Topics: Acute Kidney Injury; Humans; Hydrazines; Multiple Myeloma; Triazoles; Tumor Lysis Syndrome

2021
Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma.
    Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:12

    Topics: Humans; Hydrazines; Multiple Myeloma; Treatment Outcome; Triazoles

2021
Selinexor and dexamethasone in multiple myeloma.
    The Lancet. Oncology, 2018, Volume: 19, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Treatment Outcome; Triazoles

2018
Promising new treatment for multiple myeloma.
    The Lancet. Oncology, 2018, Volume: 19, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Humans; Hydrazines; Multiple Myeloma; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles

2018
The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
    Journal of hematology & oncology, 2015, Apr-16, Volume: 8

    Topics: Benzoates; Cell Line, Tumor; Hematopoiesis; Humans; Hydrazines; In Vitro Techniques; Megakaryocytes; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia

2015
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Caspase 10; Caspase 8; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Enzyme Activation; Humans; Hydrazines; Intracellular Space; Mice; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Triazoles; Xenograft Model Antitumor Assays

2016
Thromboxane A2 Receptor Inhibition Suppresses Multiple Myeloma Cell Proliferation by Inducing p38/c-Jun N-terminal Kinase (JNK) Mitogen-activated Protein Kinase (MAPK)-mediated G2/M Progression Delay and Cell Apoptosis.
    The Journal of biological chemistry, 2016, Feb-26, Volume: 291, Issue:9

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bridged Bicyclo Compounds, Heterocyclic; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cyclin B1; Cyclin-Dependent Kinases; Cyclooxygenase Inhibitors; Fatty Acids, Unsaturated; G2 Phase; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Leukocytes, Mononuclear; MAP Kinase Signaling System; Multiple Myeloma; Neoplasm Proteins; Receptors, Thromboxane A2, Prostaglandin H2; RNA Interference

2016
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Oligopeptides; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; Receptors, Cytoplasmic and Nuclear; RNA Interference; Time Factors; Transcription, Genetic; Transfection; Triazoles; Xenograft Model Antitumor Assays

2016
[ATTEMPT AT TREATMENT OF HODGKIN'S DISEASE AND VARIOUS HEMATOSARCOMAS WITH 1-METHYL-2-P-ALLOPHANOYL-BENZYLHYDRAZINE HYDROBROMIDE].
    Revue francaise d'etudes cliniques et biologiques, 1964, Volume: 9

    Topics: Antineoplastic Agents; Hodgkin Disease; Humans; Hydrazines; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma; Mycosis Fungoides; Neoplasms; Sarcoma

1964
American Society of Hematology--48th Annual Meeting and Exposition. Therapeutic approaches for hematological cancers. 9-12 December 2006 Orlando, FL, USA.
    IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials, Phase I as Topic; Dacarbazine; Hematologic Neoplasms; Hematology; Humans; Hydrazines; Leukemia, Myeloid; Multiple Myeloma; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-kit; Sulfonamides; Temozolomide

2007
[Our experience in the treatment of Hodgkin's disease and other reticulopathies with Ro4-6467 (Natulan)].
    Sangre, 1966, Volume: 11, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Female; Hodgkin Disease; Humans; Hydrazines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma

1966
Analysis of glycoform of O-glycan from human myeloma immunoglobulin A1 by gas-phase hydrazinolysis following pyridylamination of oligosaccharides.
    Analytical biochemistry, 1992, Volume: 206, Issue:1

    Topics: alpha-Fetoproteins; Amination; Aminopyridines; Animals; Carbohydrate Sequence; Cattle; Chromatography, Gas; Chromatography, High Pressure Liquid; Humans; Hydrazines; Immunoglobulins; Molecular Sequence Data; Multiple Myeloma; Myeloma Proteins; Oligosaccharides; Polysaccharides

1992
Carboxy-terminal amino acids of gamma-A and gamma-M heavy chains.
    Science (New York, N.Y.), 1967, Jun-23, Volume: 156, Issue:3782

    Topics: Amino Acid Sequence; Animals; Carboxypeptidases; Chromatography, Gel; gamma-Globulins; Humans; Hydrazines; Mice; Molecular Biology; Multiple Myeloma; Peptides; Plasmacytoma; Tyrosine; Waldenstrom Macroglobulinemia

1967
Immunoelectrophoretic studies on beta-1-E-globulin in human serum.
    Biken journal, 1967, Volume: 10, Issue:3

    Topics: Agar; Animals; Arthritis, Rheumatoid; Beta-Globulins; Complement System Proteins; Hemolysis; Humans; Hydrazines; Immune Sera; Immunoelectrophoresis; Liver Cirrhosis; Multiple Myeloma; Precipitins; Stomach Neoplasms

1967
Current problems in the use of the oncolytic drugs.
    Acta geneticae medicae et gemellologiae, 1968, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dactinomycin; Female; Fluorouracil; Gonadal Steroid Hormones; Hodgkin Disease; Humans; Hydrazines; Leukemia; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mesenchymoma; Methotrexate; Multiple Myeloma; Nitrogen Mustard Compounds; Ovarian Neoplasms; Pregnancy; Prostatic Neoplasms; Steroids; Testicular Neoplasms; Urethane; Vinblastine; Vincristine; Wilms Tumor

1968
[Therapy of hemoblastosis. I. Elements of cytostatic and symptomatic therapy].
    Giornale di clinica medica, 1966, Volume: 47, Issue:8

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Arsenicals; Colchicine; Hodgkin Disease; Humans; Hydrazines; Immunosuppressive Agents; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma

1966
[Personal experience on the chemotherapy of leukemias and hematosarcomas].
    Acta geneticae medicae et gemellologiae, 1968, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Drug Synergism; Hodgkin Disease; Humans; Hydrazines; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma; Mycosis Fungoides; Vinblastine; Vincristine

1968
Combination chemotherapy in malignant disease.
    Clinical radiology, 1971, Volume: 22, Issue:4

    Topics: Administration, Oral; Blood Cell Count; Breast Neoplasms; Bronchial Neoplasms; Child, Preschool; Female; Hodgkin Disease; Humans; Hydrazines; Injections, Intravenous; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Multiple Myeloma; Neoplasms; Prednisolone; Radiography; Remission, Spontaneous; Sarcoma, Ewing; Vinblastine

1971
[Symptomatic thrombopenias. Difficulties of early diagnosis and therapeutic possibilities].
    Schweizerische medizinische Wochenschrift, 1966, Sep-17, Volume: 96, Issue:37

    Topics: Adult; Blood Platelets; Hemorrhagic Disorders; Hodgkin Disease; Humans; Hydrazines; Immunoelectrophoresis; Lupus Erythematosus, Systemic; Male; Middle Aged; Multiple Myeloma; Prednisone; Purpura; Splenectomy; Thrombocytopenia; Vinblastine; Waldenstrom Macroglobulinemia

1966
[Experiences with methyl-benzyl-hydrazine (Natulan) in lymphoreticular diseases and hemoblastoses].
    Blut, 1968, Volume: 18, Issue:1

    Topics: Anemia, Hemolytic, Autoimmune; Arthritis, Rheumatoid; Carcinoma; Colitis, Ulcerative; Eosinophilia; Humans; Hydrazines; Leukemia, Lymphoid; Leukopenia; Lymphocytes; Lymphoma; Mast Cells; Multiple Myeloma; Nephrotic Syndrome; Polycythemia Vera; Time Factors; Waldenstrom Macroglobulinemia

1968
Cytotoxic agents in the treatment of malignant disease.
    British medical journal, 1968, Nov-16, Volume: 4, Issue:5628

    Topics: Antimetabolites; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chlorambucil; Choriocarcinoma; Cyclophosphamide; Female; Fluorouracil; Hodgkin Disease; Humans; Hydrazines; Intestinal Neoplasms; Melphalan; Methotrexate; Multiple Myeloma; Ovarian Neoplasms; Pregnancy; Thiotepa; Vinblastine

1968
[Therapy of malignant hemopathies].
    Praxis, 1966, Jun-16, Volume: 55, Issue:24

    Topics: Female; Hematologic Diseases; Humans; Hydrazines; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Multiple Myeloma; Prednisone

1966
[Methylhydrazine in the treatment of multiple myeloma and Hodgkin's disease].
    Schweizerische medizinische Wochenschrift, 1965, Oct-23, Volume: 95, Issue:43

    Topics: Adult; Aged; Female; Hodgkin Disease; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma

1965